Research-based biopharmaceutical company AbbVie has announced the availability of new, higher-dose of Creon (pancrelipase) delayed-release capsules in the US.
Indicated for patients with exocrine pancreatic insufficiency (EPI), 36,000 lipase-unit dose of the pancreatic enzyme replacement therapy was approved by the FDA.
University of Pittsburgh gastroenterology, hepatology and nutrition division chief Dr. David Whitcomb said, "A higher lipase capsule dose is an option for some patients, and it may help reduce the number of capsules they take when compared to lower lipase products."
The inability of the pancreas to produce food digesting enzymes is referred to as EPI, which can be developed by patients living with cystic fibrosis, chronic pancreatitis, pancreatectomy, and other conditions.
AbbVie global medical affairs vice president Maria Rivas said, "With the launch of this new CREON strength, healthcare professionals and patients now have access to the broadest range of dosage strengths in the PERT class."
